John Samuel snapped up 148,000 shares at 13.5p each, taking his stake in the regenerative tissue specialist to 3.7%.
Tissue Regenix’s technology uses animal or human tissue to replace damaged or worn out parts of the human body.
Its patented dCELL platform can be used to make 20-30 different products. The group's biggest focus is wound care, but it is also developing applications in the cardiac and orthopaedic markets.
The company is on track to launch its first product in the US in the first half of next year.
Tissue Regenix Woundcare, the firm’s US arm, has been recruiting heavily over the past year ahead of the launch of DermaPure, a skin repair product for chronic and acute wounds.
A processing agreement was signed in June with Community Tissue Services (CTS) to supply the tissue to be treated by dCell, while it is also close to appointing distributors.